Emerging opportunistic fungal infections: Where are we heading?

Journal of the National Medical Association

Volumn 95, Issue 12, 2003, Pages 1211-1215

  Idemyor, Vincent ^a,b,c  

^a Advocate Bethany Hospital ^*  (United States)

^b ADVOCATE HEALTH CARE   (United States)

^c UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Emerging fungi; Opportunistic fungi; Treatment

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; ECHINOCANDIN B; ERGOSTEROL; FLUCONAZOLE; IMIDAZOLE DERIVATIVE; ITRACONAZOLE; KETOCONAZOLE; LANOSTEROL; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ASPERGILLUS; CANDIDA; CRYPTOCOCCUS; FUNGUS IDENTIFICATION; HUMAN; MYCOSIS; NEPHROTOXICITY; OPPORTUNISTIC INFECTION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; ZYGOMYCETES;

EID: 0346992382     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Pinner RW, Teutsch SM, Simonsen L, et al. Trends in infectious disease mortality in the United States. JAMA. 1996;275:189-193.
2. Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. 13 Aspergillus Study Group. Medicine. 2000;79:250-260.
3. Blumberg HM, Jarvis WR, Souvie JM, et al. Risk factors for candidal bloodstream infections in surgical intensive-care-unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis. 2001;33:177-186.
4. Bow EJ, Loewen R, Cheang MS, et al. Cytotoxic Therapy-Induced D-Xylose Malabsorption and Invasive Infection During Remission-Induction Therapy for Acute Myeloid Leukemia in Adults. J Clin Oncol. 1997;15:2254-2261.
5. Borzotta AP, Beardsley K. Candida infections in critically ill trauma patients: a retrospective case-control study. Arch Surg. 1999;134:657-664.
6. McNeil MM, Nash SL, Hajjeh RA, et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis. 2001;33:641-647.
7. Rees JR, Pinner RW, Hajjeh RA, et al. The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992-1993: results of population-based laboratory active surveillance. Clin Infect Dis. 1998;5:1138-1147.
8. Wald A, Leisenring W, van Burik JA, et al. Epidemiology of Aspergillus in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis. 1997;175:1459-1466.
9. Sugar AM. Agents of mucormycosis and related species. In: Mandell GL, Bennett JE, Dolin E, eds. Principles and Practice of Infectious Diseases. 4th ed. New York, NY: Churchill Livingstone; 1995:2311-2321.
10. Bennett JE. Miscellaneous fungi and prototheca. In: Mandell GL, Bennett JE, Dolin E, eds. Principles and Practice of Infectious Diseases. 4th ed. New York, NY: Churchill Livingstone; 1995:2389-2392.
11. Stringer JR, Cushion MT, Wakefield AE. New nomenclature for the genus Pneumocystis. J Eukaryot Microbiol. 2001; Suppl:184S-189S.
12. Stringer JR. Pneumocystis. Int J Med Microbiol. 2002;292:391-404.
13. Stringer JR, Beard CB, Miller RF, et al. A new name (Pneumocystis jiroveci) for Pneumocystis from humans. Emerg Infect Dis. 2002;9:891-896.
14. Kaplan JE, Hanson D, Dworkin MS, et al. Epidemiology of HIV-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis. 2000;30(suppl 1):S5-S14.
15. Shelburne III SA, Hamill RJ, Rodriguez-Barradas MC, et al. Immune Reconstitution Inflammatory Syndrome: Emergence of a Unique Syndrome During Highly Active Antiretroviral Therapy. Medicine. 2002;81:213-227.
16. Cinti SK, Armstrong WS, Kauffman CA. Case report. Recurrence of increased intracranial pressure with antiretroviral therapy in an AIDS patient with cryptococcal meningitis. Mycoses. 2001;44:497-501.
17. Wislez M, Bergot E, Antoine M, et al. Acute respiratory failure following HAART introduction in patients treated for Pneumocystis carinii pneumonia. Am J Respir Crit Care Med. 2001;164:847-851.
18. Groll AH, Piscitelli SC, Walsh TJ. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol. 1998;44:343-501.
19. Hiemenz JW, Walsh TJ. Lipid formulations of amphotericin-B: recent progress and future directions. Clin Infect Dis. 1996;22(suppl 2):S133-S144.
20. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin-B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408-415.
21. Hoang A. Caspofungin acetate: an antifungal agent. Am J Health Syst Pharm. 2001;58:1206-1214.
22. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin-B for invasive candidiasis. N Engl J Med. 2002;347:2020-2029.